SOMNOMED LIMITED (SOM)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
SOM - SOMNOMED LIMITED
FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -61.51
Index:
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.44
01 Dec |
0.000 OPEN $0.44 |
0.000 HIGH $0.44 |
0 LOW $0.44 |
| OTHER COMPANIES IN THE SAME SECTOR | |||
| 4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . TRJ . UBI . VHT . VTI . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
| Title | FY21 Actual |
FY22 Actual |
FY23 Forecast |
FY24 Forecast |
|---|---|---|---|---|
| EPS (cps) | xxx | - 5.4 | N/A | xxx |
| DPS (cps) | xxx | 0.0 | N/A | xxx |
| EPS Growth | xxx | N/A | N/A | xxx |
| DPS Growth | xxx | N/A | N/A | xxx |
| PE Ratio | xxx | N/A | N/A | xxx |
| Dividend Yield | xxx | N/A | 0.0% | xxx |
| Div Pay Ratio(%) | xxx | N/A | N/A | xxx |
Dividend yield today if purchased 3 years ago: 0.00%
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -9.7 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 83.6 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 25.9 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -3.9 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -9.41 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -31.35 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -20.57 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -13.05 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -31.35 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -9.50 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -7.0 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 3 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 21 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 24 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 6 M |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 12 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 3.53 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 6.4 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 7.67 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 38 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 50 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 1 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
SOM STOCK CHART
FNArena News on SOM
| 1 |
Australian Broker Call *Extra* Edition – Nov 08, 2023Nov 08 2023 - Daily Market Reports |
| 2 |
Australian Broker Call *Extra* Edition – Oct 09, 2023Oct 09 2023 - Daily Market Reports |
| 3 |
Australian Broker Call *Extra* Edition – Jul 31, 2023Jul 31 2023 - Daily Market Reports |
| 4 |
Australian Broker Call *Extra* Edition – Mar 06, 2023Mar 06 2023 - Daily Market Reports |
| 5 |
FNArena Corporate Results Monitor – 24-02-2023Feb 24 2023 - Australia |
Latest Medical Equipment & Devices News
| 1 |
Dr Boreham’s Crucible: Pro MedicusOct 23 2023 - Australia |
| 2 |
Dr Boreham’s Crucible: CyclopharmOct 09 2023 - Small Caps |
| 3 |
Dr Boreham’s Crucible: PainchekSep 11 2023 - Small Caps |
| 4 |
Margins Signal Integral Diagnostics RecoverySep 07 2023 - Australia |
| 5 |
ResMed: Finding A Base?Aug 15 2023 - Technicals |
| 6 |
August Turns ResMed Into Nigel NoMatesAug 09 2023 - Australia |
| 7 |
Dr Boreham’s Crucible: Lumos DiagnosticsJun 19 2023 - Small Caps |
| 8 |
Fisher & Paykel Healthcare: Lower Margin, Higher SpendingMay 30 2023 - Australia |
| 9 |
Dr Boreham’s Crucible: ImpedimedMay 08 2023 - Small Caps |
| 10 |
Treasure Chest: ResMed’s Benevolent MonopolyMay 01 2023 - Treasure Chest |
